Skip to content
News & Publications
News
Publications
Contact Us
About Us
History
Patents
Technology
Signaling Chain HOmoOLigomerization (“SCHOOL”) Platform Basics
Macrophage Modulation
Macrophage Imaging
Pipeline
Therapeutic Areas
Cancer
Autoimmune Diseases
Retinopathy
Atherosclerosis
Sepsis/ARDS & COVID
Other Inflammatory Diseases
Partners & Collaborators
Menu
Understanding Nature. Improving Life
Type and press enter to search
SignaBlok awarded NCI / NIH SBIR Phase I grant to test new approach to lung cancer treatment
SignaBlok
>
News
>
SignaBlok awarded NCI / NIH SBIR Phase I grant to test new approach to lung cancer treatment
SignaBlok
>
News
>
SignaBlok awarded NCI / NIH SBIR Phase I grant to test new approach to lung cancer treatment
SignaBlok awarded NCI / NIH SBIR Phase I grant to test new approach to lung cancer treatment
Post navigation
Previous Post
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new nanotechnology for diagnostic imaging of atherosclerosis
Next Post
Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages
Vera
View posts by Vera
Scroll to top
close ×
